Reason for request
Reassessment
Clinical Benefit
| Substantial |
Considering all these elements, the Committee deems that the clinical benefit of KYMRIAH 1.2 x 10^6 – 6 x 10^8 cells (tisagenlecleucel) dispersion for infusion remains substantial in “the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy” and at the MA dosages.
|
Clinical Added Value
| minor |
Considering:
- additional experience with respect to the real-world data for KYMRIAH (tisagenlecleucel) in the French DESCAR-T registry (26 activated centres, 388 treated patients, median follow-up of 15 months since eligibility), which are consistent with the clinical data (JULIET),
- the role of KYMRIAH (tisagenlecleucel) compared to YESCARTA (axicabtagene ciloleucel), which remains difficult to determine given the major methodological limitations of the indirect comparison provided,
- the safety profile marked by significant short-term toxicity,
- and the initial uncertainties identified, which persist despite the Transparency Committee’s requests, particularly with respect to:
- the exact effect size compared to historic management, in the absence of any robust comparison,
- maintenance of the clinical efficacy in the medium and long term, particularly concerning achievement of full recovery for patients in lasting remission,
- and the absence of medium and long-term safety data,
The Committee considers that its previous conclusions are not liable to be modified. On the basis of currently available data, the Committee deems that KYMRIAH 1.2 x 10^6 – 6 x 10^8 cells (tisagenlecleucel) dispersion for infusion provides a minor clinical added value (CAV IV) in terms of efficacy compared to the historic management of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy, based on various chemotherapies.
|
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
U9WEAmsW9etT0JQa